• Journal Article

Patient preferences for treatments to delay bone metastases


Hauber, A., Arellano, J., Qian, Y., Gonzalez, J., Posner, J., Mohamed, A., ... Body, J-J. (2014). Patient preferences for treatments to delay bone metastases. Prostate, 74(15), 1488-1497. DOI: 10.1002/pros.22865


Most patients with advanced prostate cancer (PCa) develop bone metastases (BM) and present with bone complications like fracture. Bone-targeted agents that prevent metastasis-induced bone complications can cause adverse events. Understanding how patients view treatment options may optimize care. This study aimed to quantify how PCa patients value a hypothetical treatment that delays BM but can cause osteonecrosis of the jaw (ONJ). The study also assessed the value patients place on avoiding metastasis-induced bone complications versus increased survival.

PCa patients from the United Kingdom (n?=?201) and Sweden (n?=?200) on androgen-deprivation therapy or hormone therapy for ??3 years completed a 10-question discrete-choice-experiment survey examining whether patients would accept a BM-delaying treatment. Two time-tradeoff questions assessed patients' willingness to tradeoff between survival and bone complications. Percentages of patients choosing treatment were summarized by levels of treatment efficacy and ONJ risk. Odds ratios from a logit model were used to evaluate how patient and medication characteristics affected treatment choice. Proportions of patients choosing each tradeoff scenario were calculated.

A majority of patients accepted treatment at the lowest benefit level (5-month BM delay) and highest risk level (9% ONJ risk). PCa symptoms and prior treatment affected patient preferences. Nearly 80% of patients would tradeoff at least 3 months of survival to avoid bone complications.

PCa patients in the UK and Sweden may value a medication that delays BM, despite the risk of ONJ. Furthermore, patients were willing to tradeoff up to 5 months of survival for prevention of bone complications. Prostate © 2014 Wiley Periodicals, Inc.